We herein present a case of carcinosarcoma arising as a primary lesion in the spleen with the presence of local invasion of chest wall prior to widespread metastasis all over the body of a female aged 64 years. The detailed information of therapy and imaging evidences of morphology, histology, and immunohistochemistry are fully provided. To the best of our knowledge, this is the fifth reported case of a primary splenic carcinosarcoma and even the first case to be described with local invasion in the mongoloid. Carcinosarcoma that develops in the spleen with local invasion is extremely rare.
Introduction
Carcinosarcomas, containing both epithelial and connective tissue components, are rare malignant neoplasms, which commonly arise from the female genital tract (Steeper et al., 1983; Gadducci and Romanini, 2001; Cicin et al., 2008) , and sometimes from extragenital sites (Isimbaldi et al., 1996; di Vizio et al., 2001) . Carcinosarcomas originating in the spleen are extraordinarily rare. There have been no more than four reported cases of primary carcinosarcomas of the spleen in English-language literature. Westra et al. (1994) reported the first case of primary splenic carcinosarcoma, which was thought to arise from the mesothelium, reflecting the unique capacity of the female mesothelium for mullerian differentiation. Rao et al. (2007) reported a case of splenic carcinosarcoma of a male, which was characterized by the presence of an osteosarcomatous element and raised β human chorionic gonadotropin (β-hCG) levels. Kochar et al. (2009) presented a Caucasian man with a high-grade malignant pleomorphic tumor with areas of necrosis, and this case revealed osteosarcomatous differentiation and a spindle and epithelioid morphology. Most recently, Joy et al. (2012) reported another case of primary splenic carcinosarcoma. However, no imaging evidence of morphology, histology, or immunohistochemistry was provided. Herein, we report a case of carcinosarcoma arising as a primary lesion in the spleen of a female aged 64 years. The feature of this tumor is the presence of local invasion of the chest wall prior to wide metastasis all over the body. As far as we are aware, this is the fifth reported case of a primary splenic carcinosarcoma and the first case to be described with the local invasion in the mongoloid.
Case presentation
The patient is a 64-year-old mongoloid female who was admitted with persistent dull pain of the left middle trunk, limited to the left upper quadrant and left lower anterior chest wall. She denied any other symptoms, except for occasional shortness of breath. She gave a medical history of hypertension. On physical examination, there was tenderness in the left upper quadrant and left lower anterior chest wall. There were no palpable lymph nodes or mass, and chest examination revealed decreased breath sound of the left lung. Blood analysis showed an elevated white cell count (11.4×10 9 cells/L) and mild anaemia. The analysis of tumor markers showed elevated carcinoembryonic antigen (CEA, 12.95 ng/ml), cancer antigen 125 (CA125, 1041.90 U/ml), and CA153 (119.70 U/ml). The other markers including CA199 and alphafetoprotein (AFP), as well as other hematological and biochemical parameters, were normal. Chest radiograph showed a moderate amount of effusion of the left pleural cavity (Fig. 1a) , and percutaneous drainage was performed. Abdominal ultrasound showed a markedly enlarged spleen with a diameter of 22 cm, with a mass of abnormally high echogenicity in the lower splenic pole and areas of low echogenicity within the spleen, but no ascites. Computed tomography (CT) showed a high-density mass in the lower pole of the spleen (Fig. 1b) , accompanied by multiple cystic solid mass in the spleen and a 6.1 cm×3.6 cm mass shadow with the bone destruction of the left anterior fifth rib (Fig. 1c) . The upper gastrointestinal endoscopy, as well as colonoscopy, was also performed without positive findings. The positron emission tomography/computed tomography (PET/CT) scan confirmed multiple lowdensity mass and one high-density mass distributed in the spleen, and a soft tissue mass shadow with local rib destruction (Figs. 1d and 1e ). There were no other abnormalities found on the PET/CT. Accordingly, primary splenic malignancy was first considered. Then the persistent severe pain caused by the tumors had brought an intolerable burden on her body and mentality. This patient has no pertinent family history, In consideration of the limited distribution of tumors, the palliative splenectomy in combination with resection of the rib tumor was performed. An open radical resection was performed (Yan et al., 2015) and the operation showed an enlarged spleen adhesive to the surrounding chest wall, splenic flexure of colon and diaphragm. The other internal organs were entirely normal.
The tissue samples were prepared and embedded in paraffin. The paraffin blocks were sectioned to a thickness of 5 µm and stained with hematoxylin and eosin (H&E). Stained sections were visualized under an optical microscope. The procedures of immunohistochemistry were performed on an automated Ventana BenchMark immunostainer (Roche, Basel, Switzerland) at the Department of Pathology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, China.
Postoperatively, the intractable pain was obviously relieved, and even disappeared. One month post operation, follow-up indicated that this patient recovered well without evident recurrence of tumor and could do some housework.
The patient was then reviewed by an oncologist who advised treatment with palliative chemotherapy, consisting of cisplatin and etoposide.
Results

Gross observation
The spleen was enlarged, weighing 2980 g and measuring 25 cm×15 cm×15 cm. The external surface was bosselated, and the cut surface revealed an undefined, heterogenous soft mass in the lower pole, measuring up to 9.0 cm×8.0 cm×4.2 cm (Fig. 2a) . The dividing line was not clear all round the mass, and there was no obvious coating observed. The multiple cystic solid mass proved to be hematoncus.
The rib mass appeared as a soft grayish-white mass with the size of 4.0 cm×3.0 cm×2.0 cm, and adhered seriously to the surrounding bone and intercostal muscles.
Optical microscopy
Histological images showed a low-grade malignant tumor of patchy distribution, accompanied by areas of necrosis. The neoplasm without coating invaded the normal tissue of the spleen. There were distinct areas of necrotic tissue. The rest of the tumor showed a spindle and epithelioid morphology on optical microscopy. The spindle tumor cells showed no distinctive atypia and fewer mitoses, while the epithelioid cells varied in size and shape, and had a (Figs. 2b-2e ). The neoplasm of chest wall also showed cellular morphologies similar to the splenic malignancy. The tumor tissue, invading the surrounding striated muscle and encompassing the nerve fiber, was also observed (Figs. 2f and 2g) . There was no evidence of any glandular or squamous differentiation. There were no features of any other sarcoma.
The tissue samples resected from splenic flexure of the colon and diaphragm proved histologically to be tissue hyperplasia caused by chronic inflammation.
Immunohistochemistry
For immunohistochemical analysis, the tumor cells revealed strong immunoreactivity for vimentin (Fig. 2h) . There was patchy but convincing positivity for cytokeratin (CK; pan) and epithelial membrane antigen (EMA) (Figs. 2i and 2j) . The tumor cells were negative for F8, CD31, CD34, SMA, Desmin, S100, HMB-45, Calretinin, HBME-1, and TTF-1, and focally weakly positive for CD68.
To summarize, this was a poorly differentiated malignant tumor with essentially 2 components, i.e. the spindle and epithelioid components. This is consistent with a carcinosarcoma showing heterologous differentiation.
Discussion
Carcinosarcomas are rare biphasic malignant tumors. Histological analysis of tumors has shown characteristics of epithelial carcinoma and mesenchymal differentiation. They occurred in many anatomical locations such as the female genital tract (Dave et al., 2011; Kanthan and Senger, 2011) , pelvic peritoneum (Ko et al., 2005) , breast (Cornette et al., 2005) , stomach (Iezzoni and Mills, 1993) , colon (Isimbaldi et al., 1996) , pancreas (Darvishian et al., 2002; Chmiel et al., 2005) , head and neck, respiratory system, hepatobiliary system, thyroid, thymus, and skin. A malignant mass arising within the spleen is most commonly of a lymphoreticular origin (Kochar et al., 2009) . The finding of carcinosarcoma in the spleen is very rare. In this case, sarcomatous areas consisted of uniform spindle cells, while carcinomatous areas were composed of irregular granular cells with frequent megakaryocytes.
The signs and symptoms for primary splenic malignancy lack specificity. Many preoperative and/or postoperative examinations, such as physical examination, abdominal ultrasound, CT scan, and endoscopic examination of the gastrointestinal tract, have to be conducted to exclude the metastatic neoplasms prior to the diagnosis of primary splenic tumor (Kochar et al., 2009 ). In our limited experience, PET/CT could be helpful to the above procedures. In addition, the collision tumor representing synchronous carcinoma and sarcoma from separate sources (Thompson et al., 1996) , and endometriosis-associated extragenital carcinosarcomas (Booth et al., 2004) , should also be differentially diagnosed from primary carcinosarcoma of the spleen.
The histogenesis and biological behavior of carcinosarcoma are not fully understood. Surface mesothelium has been proposed as the origin of splenic epithelial tumors (Rao et al., 2007) . Some people stated that such tumors arose from invaginated mesothelium of malignant transformation or a preexisting embryonic rest (Morinaga et al., 1992; Rao et al., 2007) . We are more inclined to believe that the neoplasm in this case probably arose directly from the spleen, in the absence of evidence to support metastasis from other sites. So far, the survival time of splenic carcinosarcoma patients post operation ranged from 3 to 12 months (Westra et al., 1994; Rao et al., 2007; Kochar et al., 2009; Joy et al., 2012) . This may be because of the rapid spread and highly invasive nature of these lesions (Rao et al., 2007) . The metastatic paths of carcinosarcoma could include the bloodstream and lymphatic metastasis, local spread, and so on. In our case, only local metastasis of the chest wall occurred, and resulted in severe pain, which could be related to the early stage of this tumor. Follow-up observation will determine whether other metastasis happened subsequently.
To date, there are no guidelines available for the treatment of splenic carcinosarcoma. It is generally agreed that complete macroscopic excision of the malignancy may provide the best chance of survival (Kochar et al., 2009) . Postoperatively, adjuvant treatments, such as chemotherapy and radiotherapy, should be under consideration to further kill the tumor cells and improve the prognosis of patients. For chemotherapy, both the carcinomatous and the sarcomatous components have to be addressed. There is no consensus concerning optimal chemotherapeutic regimes (Kochar et al., 2009) . Ifosfamide and cisplatin combination therapy has been reported to offer a better survival rate (Ko et al., 2005) . Cyclophosphamidedoxorubicin-containing chemotherapy has been suggested for breast carcinosarcoma (Cornette et al., 2005) . Some researchers stated that carcinosarcomas responded better to cisplatin-based regimes (Gadducci and Romanini, 2001) . Some other regimens, such as ovarian-type chemotherapeutic regimens combining cisplatin, etoposide, cyclophosphamide, doxorubicin and paclitaxel, sarcoma-type regimens combining doxorubicin, ifosfamide, and dacarbazine, were also reported for carcinosarcomas (Resnik et al., 1995; Cass et al., 1996; Cicin et al., 2008) . For splenic carcinosarcoma, Kochar et al. (2009) applied cisplatin and etoposide combination therapy to treat a 60-yearold Caucasian man, who died 7 months after diagnosis attributed to the wide metastasis. Although various combinations of chemotherapy have been explored, an optimal therapeutic modality is yet to be determined (Kanthan and Senger, 2011) .
Adjuvant radiotherapy has been used to treat carcinosarcoma (Park et al., 2011) . However, its value in addition to systemic treatment remains ill-defined (Dave et al., 2011) . Park et al. (2011) investigated the influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma, and indicated that adjuvant radiotherapy after surgical resection was effective in decreasing loco-regional recurrence, and most treatment failures were due to distant metastasis. The combined chemoradiotherapeutic approach has also been adopted and has shown survival benefit for uterine carcinosarcoma patients (Galaal et al., 2009) . In brief, multimodal therapy including surgery, radiotherapy, and chemotherapy might be an optimal treatment. Ko et al. (2005) reported a case of a primary carcinosarcoma of the pelvic peritoneum with five-year disease-free survival after managing the patient with surgery, chemotherapy, and radiotherapy.
Evidence gained from the above regimens for carcinosarcomas of different original sites may be beneficial for the treatment of the splenic tumor. It seems unlikely to be able to conduct any trial to test different regimes, because these tumors are so rare. Regardless of the treatment, the prognosis of carcinosarcoma is universally poor.
Conclusions
Splenic carcinosarcoma is a rare tumor with embryological origin. There have been just four previously reported cases of primary splenic carcinosarcoma. Every effort should be made to carefully exclude other primary sites before reaching the diagnosis of primary carcinosarcoma. There is no consensus regarding the optimal treatment strategy for this disease. Multimodal therapy including surgery, radiotherapy, and chemotherapy might be an optimal treatment. The prognosis of carcinosarcoma is universally poor.
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